AOD-9604: A Research Overview
What AOD-9604 is, where it came from, and what laboratory research does and does not support about this growth-hormone fragment.
Read articleAn overview of three central metabolic receptors and the design logic behind peptides engineered to act on more than one of them.
GLP-1, GIP and glucagon receptors sit at the centre of the biggest shift in metabolic research in a decade. Understanding how the three interact explains why newer peptides are engineered to hit more than one at once.
GLP‑1, GIP and glucagon receptors together represent the most actively investigated hormone system in metabolic science today, and their interplay is reshaping how researchers think about energy balance and glucose control.
Scientists are asking a series of focused questions that cut across basic biology, disease modelling and potential therapeutic concepts. Each question reflects a gap in our understanding and a possible route to new insights.
All three receptors belong to the family of G‑protein‑coupled receptors (GPCRs), membrane proteins that translate an external signal into an internal cellular response. When a peptide binds to GLP‑1 or GIP receptors, the receptor activates the enzyme adenylate cyclase, raising cyclic AMP levels and prompting insulin‑producing β‑cells to release more insulin. In contrast, glucagon receptor activation stimulates a separate signalling cascade that raises blood glucose by promoting hepatic glucose production and increasing lipolysis (fat breakdown). Researchers hypothesise that a carefully balanced activation of the three pathways could tip the metabolic scale toward improved glucose handling while also boosting calorie burning, but the exact wiring of these signals remains under investigation.
In cultured pancreatic beta‑cell lines, GLP‑1 receptor agonists increase insulin gene expression and secretion when glucose is present, confirming the classic potentiation effect. Parallel experiments with adipocyte (fat‑cell) cultures show that GIP receptor activation can enhance lipid uptake, but only under certain nutrient conditions, suggesting a context‑dependent role. Researchers using hepatocyte (liver‑cell) models report that glucagon receptor engagement raises enzymes involved in glucose output, mirroring the hormone’s natural function. When a single synthetic peptide that can bind all three receptors is added to a mixed cell system, investigators observe a modest increase in both insulin release and fatty‑acid oxidation, hinting at a coordinated response.
Rodent studies provide the next layer of evidence. In diet‑induced obesity mice, chronic GLP‑1 receptor activation leads to lower fasting blood glucose and modest weight stabilization, while GIP receptor activation alone does not consistently affect body weight. When glucagon receptors are stimulated, mice show a rise in energy expenditure measured by indirect calorimetry, but also a temporary increase in blood glucose. Importantly, animals given a tri‑agonist peptide that hits all three receptors display a combined pattern: modestly lower glucose, a small but measurable rise in metabolic rate, and no dramatic changes in food intake. These findings suggest additive, but not simply additive, effects across the three pathways.
Human data are still limited. Small early‑phase studies have examined GLP‑1 receptor agonists as single agents, showing the expected rise in insulin after meals. Separate trials with GIP‑focused compounds have produced mixed signals, with some reporting enhanced post‑prandial insulin and others showing little effect. Glucagon receptor agonists have been explored mainly to understand their impact on metabolic rate, and results indicate a slight increase in energy expenditure but also a rise in circulating glucose. To date, no peer‑reviewed study has evaluated a single peptide that simultaneously activates all three receptors in people, leaving a clear gap between animal findings and human translation.
The most widely studied single‑receptor agents are GLP‑1 analogues such as semaglutide, which have a well‑characterised effect on insulin secretion and appetite control. GIP‑centric compounds like tirzepatide add a second target, and early research suggests they may broaden metabolic benefits, yet they still fall short of directly engaging glucagon pathways. By contrast, tri‑agonist designs aim to capture the glucose‑lowering power of GLP‑1, the nutrient‑sensing role of GIP, and the energy‑burning signal of glucagon in one molecule. This integrated approach differentiates them from the more incremental dual‑agonists currently in clinical pipelines.
Key uncertainties remain. The optimal balance of activation across the three receptors has not been defined, and excessive glucagon signalling could negate glucose‑lowering benefits. Long‑term safety data, especially regarding pancreatic or liver stress, are absent because most studies have been short‑term animal experiments. Delivery methods that preserve peptide stability while reaching the intended targets are still under development, and it is unclear how genetic differences among individuals might modulate response. Until these gaps are addressed, conclusions about therapeutic potential remain speculative.
Operator’s desk: Many of the published cell‑based assays use peptide concentrations far higher than those achievable in vivo, so results should be interpreted with caution when extrapolating to whole‑organism physiology.
The information provided here is for research and educational purposes only. The peptides discussed are not listed on the Australian Register of Therapeutic Goods (ARTG) and must not be used for human or animal consumption.
Links lead to the original paper, DOI record, or open-access full text where available.
This compound is supplied for in vitro laboratory and educational research only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth). Not for human or animal consumption, therapeutic use, or diagnostic procedures. By purchasing, you confirm you are a qualified researcher or acting on behalf of a licensed research facility, and you assume full responsibility for the safe handling, storage, and lawful use of this compound.

What AOD-9604 is, where it came from, and what laboratory research does and does not support about this growth-hormone fragment.
Read article
A research-focused look at the synthetic tetrapeptide Epitalon, its study context, and what telomere research can responsibly support.
Read article
An evidence-led overview of Selank, its origin as a tuftsin analogue, and the boundaries of the research around stress and immune signalling.
Read article
A summary of KPV (Lys-Pro-Val), the cell and animal research behind it, and the limitations of the existing evidence.
Read articleTell us what you need. An email address is required so we can reply.